Read news on cell lymphomas with our app.
Read more in the app
Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study
Johns Hopkins scientists develop targeted therapy for t-cell lymphomas and leukemias - EurekAlert!
Enzyme identified as an important tumor inhibitor in T-cell lymphomas
Risks of tisagenlecleucel therapy for relapsed or refractory b-cell lymphomas - EurekAlert
